Related Experiment Video
Updated: May 25, 2026

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
Pathological and molecular biological approaches to early mesothelioma
Tohru Tsujimura1, Ikuko Torii, Ayuko Sato
1Department of Pathology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan. tohru@hyo-med.ac.jp
Abstract:
Malignant mesothelioma is an asbestos-related malignancy that arises primarily from mesothelial cells on the serosal surfaces of the pleural, peritoneal, and pericardial cavities. Malignant pleural mesothelioma (MPM) is most common, and its incidence is dramatically increasing worldwide as a result of widespread use of asbestos. Morphological discrimination between MPM and reactive mesothelial hyperplasia is difficult, and the most reliable pathological criterion for malignancy is mesothelial proliferation invading deeply into subpleural adipose tissues. To establish radical cure of MPM, it is crucial to find early-stage MPM of epithelial type, in which mesothelial proliferation is localized on the serosal surface of parietal pleura or limited within the submesothelial fibrous tissues of parietal pleura. The initial clinical presentation for patients with MPM is frequently dyspnea and/or chest pain due to large pleural effusion, and cytological analysis of pleural effusions is valuable to find patients with early-stage MPM of epithelial type. Recently, cytological features of MPM in pleural effusion, molecular markers for MPM, and genetic alternations of MPM have been reported. In this review, we discuss major issues on pathological and molecular biological approaches for diagnosis of early-stage MPM of epithelial type.
Insights
Diagnosing early-stage malignant pleural mesothelioma (MPM) is challenging. This review focuses on pathological and molecular diagnostic approaches for early epithelial-type MPM, crucial for effective treatment.
Area of Science:
- Oncology
- Pathology
- Molecular Biology
Background:
- Malignant mesothelioma is an asbestos-related cancer affecting serosal surfaces.
- Malignant pleural mesothelioma (MPM) incidence is rising globally due to asbestos exposure.
- Distinguishing MPM from reactive hyperplasia is difficult; deep invasion is a key malignancy indicator.
Purpose of the Study:
- To review pathological and molecular diagnostic strategies for early-stage epithelial-type MPM.
- To highlight the importance of early detection for radical cure of MPM.
- To discuss recent advancements in cytological features, molecular markers, and genetic alterations in MPM.
Main Methods:
- Review of existing literature on MPM diagnosis.
- Analysis of pathological criteria for malignancy.
- Exploration of molecular markers and genetic alterations in MPM.
Main Results:
- Early-stage epithelial MPM requires localized proliferation on the parietal pleura.
- Pleural effusion cytology is valuable for detecting early epithelial MPM.
- Recent research has identified novel cytological features and molecular markers.
Conclusions:
- Accurate diagnosis of early-stage MPM is critical for treatment.
- Pathological and molecular approaches are essential for diagnosing early epithelial MPM.
- Continued research into diagnostic markers will improve patient outcomes.

